138 results
8-K
EX-99.1
FGEN
FibroGen Inc
25 Jul 23
FibroGen Announces Leadership Transition
8:32am
as Chief Marketing Officer (Vice President of Global Marketing, Strategy and Alliance Management) for Lilly Diabetes, leading the development and launch … as a seasoned
executive with extensive strategy, brand building and leadership experience. Mr. Wettig received his M.B.A. and B.A. in biology from Washington
8-K
EX-99.1
FGEN
FibroGen Inc
6 Dec 18
Fibrogen Appoints Maykin Ho, PH.D., to Board of Directors
6:09am
of knowledge in the biotechnology industry, as a new Board member,” said Thomas B. Neff, CEO. “Dr. Ho brings extensive experience in global strategy … strategy, future plans and prospects, including statements regarding the development of the company’s product candidates pamrevlumab and roxadustat
8-K
EX-99.1
FGEN
FibroGen Inc
18 May 23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
7:35am
-Looking Statements
This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, the development … .
Corporate Strategy / Investor Relations
mtung@fibrogen.com
Media:
Meichiel Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com
8-K
EX-99.1
FGEN
FibroGen Inc
16 Aug 21
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
5:23pm
release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development … .
Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
415.978.1434
mtung@fibrogen.com
Media:
GCI Health
FibroGenMedia@gcihealth.com
8-K
EX-99.1
FGEN
FibroGen Inc
5 Jun 19
Fibrogen Appoints Suzanne Blaug to Board of Directors
5:15pm
in commercial strategy and management and bringing new biopharmaceutical products to market in numerous therapeutic areas globally will be an invaluable … regarding our strategy, future plans and prospects, including statements regarding the development of roxadustat and pamrevlumab, the potential safety
8-K
EX-99.1
u5l2q2qj
7 Apr 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
fzw7 m5st2r5r8b
6 Jan 20
Fibrogen Names Enrique Conterno As Chief Executive Officer
5:23pm
8-K
xu7scgliiash0j45sftx
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
3t4zec
9 May 22
FibroGen Reports First Quarter 2022 Financial Results
4:09pm
8-K
EX-99.1
iknkhxaqy dk7q7c
11 Aug 21
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease
8:30am
8-K
EX-99.1
qgtz3z
6 Aug 20
FibroGen Announces New Appointments to its Board of Directors
4:06pm
8-K
EX-99.1
h0e8h6u23k17frbsbpup
17 Jun 21
FibroGen and HiFiBiO Announce Transformative Partnership to
4:16pm
8-K
EX-99.1
9m29om9wq 5szshhsdea
8 Aug 22
FibroGen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
EX-99.1
xy42pqv 2gva0357cr
6 Apr 21
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat
4:59pm
8-K
EX-99.1
j2cw03y1at
7 May 20
FibroGen Reports First Quarter 2020 Financial Results
4:09pm
8-K
EX-99.1
t3tw9jf 0cz3u3u
7 Nov 22
FibroGen Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
5y8v4y
5 Nov 20
FibroGen Reports THIRD Quarter 2020 Financial Results
4:05pm
8-K
EX-99.1
41fgf9bc4pwuwhp3uvb
10 May 21
FibroGen Reports First Quarter 2021 Financial Results
4:07pm
8-K
EX-99.1
xahu kx3my
28 Feb 22
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
4:06pm
8-K
EX-99.1
x2p7l7t
9 Nov 21
FibroGen Reports Third Quarter 2021 Financial Results
4:06pm